Conference Co-Hosts

University Of Michigan

2017 saw technology innovations, new therapies and diagnostics, value-based healthcare, and clinical protocol advancements as huge drivers, moving the needle from a one-size-fits-all model to personalized healthcare.

Some of the biggest impacts include:

  • Clearing CAR-T therapies for advanced lymphoma and Spark Therapeutics’ gene therapy for blindness by the FDA after decades of research
  • Foundation Medicine achieving FDA approval for its NGS-based FoundationOne genomic profiling cancer test, concurrent with the Centers for Medicare and Medicaid Services (CMS) issuing a preliminary national coverage determination for the test and others like it
  • Editing genes for gene therapy or controlling its expression via one of the most exciting innovations, the CRISPR-Cas9 technology, currently revolutionizing the field
  • Being able to understand and sequence complex DNA regions applying long-read technologies
  • Recognizing the importance of the microbiome and its impact on human health and translating learnings into therapies and diagnostics
  • New technologies such as liquid biopsy, cfDNA detection, and artificial intelligence/machine learning in genomics and drug discovery

The advancements were paradigm-shifting, especially when the different sectors of technology, research, healthcare, pharmaceutical, medical & equipment providers, and regulatory sectors converged.

On the technology side, big data analysis, artificial intelligence, and machine/deep learning made its mark with numerous applications in drug discovery, clinical diagnostics, and clinical trial optimization. With this rise, many companies are pushing the limits of disease understanding, diagnosis and therapy. Considering the need to automate and scale disease diagnosis, it has even been provocatively suggested that AI – once fully optimized and implemented – will one day replace human oncologists. While we see a huge uptick in AI/machine learning companies working feverishly on new solutions in this sector across the globe, we also hear doubt across the industry that AI is ready. Is it hype or reality? 2018 promises to provide insight and help clarify where we stand.

The CRISPR-Cas9 technology clearly dominated the research and applications sector promising the first set of its applications to enter clinical trials in 2018.

On the regulatory side, the FDA made strides with streamlining the development and review pathway for consumer tests that evaluate genetic health risks, approving Foundation Medicine’s FoundationOne CDx, Thermo Fisher Oncomine Dx Target Test, and Agilent’s GenetiSure Dx tests, while at the same time the FDA consumer advisory raised safety concerns related to the “Self-Administration” of illegal gene therapy products.

Medical and equipment providers continued with their delivery of powerful solutions that will impact the field of precision medicine, including Illumina’s NovaSeq, Oxford Nanopore’s GridION X5, or Mission Bio’s new Single-Cell DNA analysis platform Tapestri, to name a few.

The genetic testing sector is seeing a steady march forward with more companies providing a wider test spectrum. Color Genomics appears to be on a mission to democratize access to genetic testing via affordable and low cost cancer risk tests. The release of the Annual Report by UK Chief Medical Officer Dame Sally Davis provides evidence that genomics can improve health and prevent ill health. While this year saw a rise in testing coverages, some insurers worry about adverse selection and discrimination as the industry has not quite yet caught up with all the reimbursement demands and regulations that need to be put in place.

And then of course there is immunotherapy with its numerous successes including the newly developed CAR-T cell therapy, accompanied with Kyrmriah (Novartis) and Yescarta (Kite Pharma, now Gilead) approval, and Keytruda (Merck) becoming the first cancer treatment (anti-PD-1 immunotherapy) for (any) solid tumors based on a specific genomic profile. While the successes were celebrated, they also highlighted the new challenges of these drugs, including higher drug development process cost, and justification of the high overall therapy cost. Current Kyrmriah cost is $475K per treatment. The latter is a discussion point that the healthcare industry will surely need to address with all its stakeholders in mind as pressure from payors, advocacy groups, and providers are rising.

Astounding acquisitions (some of which went global) and massive financial investments occurred in 2017. The 1 billion dollar-valued company, GRAIL went global with the Cirina merger focusing on early cancer detection. Oxford Gene Technology was acquired by the Japanese in vitro diagnostics company Sysmex Corporation. At the same time, Invitae went on a shopping spree and acquired Ommodom’s CancerGene ConnectOn, Good Start Genetics, and CombiMatrix, focusing on enhancing their testing repertoire. Konica Minolta acquired Ambry Genetics in a $1 billion deal, and Gilead Sciences acquired Kite Pharma for $11.9 billion, again just to name a few examples. On the investment side, companies playing in artificial intelligence/machine learning (with Tempus, Sophia Genetics), digital health, and clinical genomics (Color Genomics, Counsyl, Edico Genome, Prenetics, WuXi NextCODE) seemed to be the big winners.

Last but not least, 2017 was also the year of more initiatives and large scale population studies including the new Big Data, Precision Medicine Network formed by five University of California precision medicine research centers, the recently launched Chinese Precision Medicine Initiative, the France Genome Medicine Plan, and the Precision Health at the University of Michigan Initiative, which – among other things – is focusing on opioid prescribing in the pre-surgical setting. For most studies, the aim is to better understand the link between genetics/specific genes and how they affect disease, while at the same time trying to integrate genomics for precision healthcare.

Given the paradigm shift, what better way is there than to ring in the New Year with the conference that highlights the latest significant developments changing the practice of medicine to personalized healthcare?

Be among the first to hear where the field is moving, what the next phase in this area of healthcare will look like, and how it will impact you and your business. PMWC 2018 has finalized a great lineup of speakers and representatives from 100,000 Genomics England, 23andMe, Agilent, Ambry Genetics, Foundation Medicine, GRAIL, Illumina, Invitae, Natera, Mission Bio, Oxford Nanopore, Thermo Fisher Scientific, and many more. Come join us for this information-rich gathering of the minds: it’s not too late!

Email [email protected] to inquire about being invited to the reception honoring Emmanuelle Charpentier (Max Plank Institute), Sir John Bell (Oxford University), Ronald Levy (Stanford), and Alan Ashworth (UCSF).

 

Happy New Year and Best Wishes for 2018 from the PMWC team!
650-961-8877
Don’t miss out. Join this timely conference now!
REGISTER

Late breaking: Dawn Barry leaves Illumina to lead Luna DNA -Blockchain Disrupting Healthcare Industry

“Every individual holds a valuable piece of the puzzle to understand disease and health, and researchers are all in need of more data. Discovery is hindered by putting the majority of data into small silos. Breaking down data silos and bringing individuals together will more quickly aggregate enough samples to rise above the complexity of genomics and identify disease candidates.” – Dawn Barry, President and Co-Founder, Luna DNA

Read More

Interview Dawn Barry the new President and Co-founder of Luna DNA

Q: In a sentence, what is Luna DNA going to do?

Read More

JPM18: Edico Genome, Illumina, Invitae, Regeneron, Thermo Fisher Scientific,… and the list goes on

It’s been an announcement-packed JPMorgan Healthcare Conference in San Francisco this week!

Read More

At PMWC 2018 Silicon Valley CMS Administrator Seema Verma Discusses the Future of Health Care

Genomics-based testing or new immunotherapies that revolutionize cancer care are changing how we approach disease…

Read More

Interview with Dr. Frank Lee, Global Healthcare & Life Sciences Industry Leader at IBM; Chief Architect, IBM Reference Architecture for Genomics – Speaker at PMWC 2018 Silicon Valley

Q: As a pioneer in high performance architectures for genomic research what are the biggest challenges that you see clients dealing with as they invest in precision medicine initiatives?

Read More

Q&A with Ira Mellman, PhD, Vice President, Cancer Immunology, Genentech – Speaker at PMWC 2018 Silicon Valley

Q: Immunotherapy is considered a huge game-changer and holds a lot of promises. Is the hype around immunotherapy justified? What are some of the exciting developments in the recent years?

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

Read More

Q&A with Matthew Kane, Co-founder & CEO, Precision BioSciences – Speaker at PMWC 2018 Silicon Valley

Q: What are the benefits of the Precision BioSciences’ ARCUS genome editing platform and what makes it unique?

Read More

Q&A with Jon Heimer, CEO, Olink Proteomics – Speaker at PMWC 2018 Silicon Valley

Q: Olink has been rapidly growing its’ library of human protein biomarker assays. What are the popular clinical applications for your biomarker panels?

Read More

2017 Review: A Clear Paradigm Shift from a one-size-fits-all model to personalized healthcare

2017 saw technology innovations, new therapies and diagnostics, value-based healthcare, and clinical protocol advancements as huge drivers, moving the needle…

Read More

Q&A with Peter Donnelly, Director, Wellcome Trust Centre for Human Genetics (Oxford) – Speaker at PMWC 2018 Silicon Valley

Q: How will genomics transform healthcare and how will it impact medicine? Beyond genetics and genomics what other data is relevant and why?

Read More

PMWC Interview with Janusz Dutkowski, Ph.D., Co-founder & CEO, Data4Cure – Speaker at PMWC 2018 Silicon Valley

Q: What are some of the key unique ideas behind the Biomedical Intelligence Cloud? What contextual knowledge do you bring in?

Read More

Q&A with Bob Terbrueggen, President & CEO, DxTerity – Speaker at PMWC 2018 Silicon Valley

Q: What are the challenges that the field of genomic research will face in the next five years?

Read More

Q&A with Mark Kiel, CSO and Co-founder, Genomenon – Speaker at PMWC 2018 Silicon Valley

Q: What are the challenges facing clinical interpretation of NGS data today?

Read More

Precision Medicine Jan 22-24th – learn from the experts at PMWC Silicon Valley 2018

Genomic Data Analysis / Next-Gen Sequencing, Immunotherapy / Cancer Care, & Artificial Intelligence / Machine Learning are all extensively covered at the conference, January 22-24

Read More
University of Michigan

About us:
The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

    • More than 70 sessions with 350+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Four tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Immuno-oncology
    • Cancer and rare disease diagnostics
    • Biomarker and companion diagnostics
    • Big data approaches
    • NGS applications
    • AI and machine learning applications
    • Advancements in liquid biopsy applications
    • Wellness & Aging
    • CRISPR
    • The human microbiome
    • Infectious disease ID and monitoring
    • The importance of patient engagement
    • 3-D technologies
    • Updates on data and regulatory policies
    • Metabolomics in precision medicine
    • mHealth and Telehealth

About us:
The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

    • More than 70 sessions with 350+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Four tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Immuno-oncology
        • Cancer and rare disease diagnostics
        • Biomarker and companion diagnostics
        • Big data approaches
        • NGS applications
        • AI and machine learning applications
        • Advancements in liquid biopsy applications
        • Wellness & Aging
        • CRISPR
        • The human microbiome
        • Infectious disease identification and monitoring
        • The importance of patient engagement
        • 3-D technologies
        • Updates on data and regulatory policies
        • Metabolomics in precision medicine
        • mHealth and Telehealth

One track will be dedicated to the various aspects of the All of Us Research Program, while another session will focus on educating California’s legislators.

 

Confirmed thought leaders include:

Sir John Bell

Sir John Bell

Regius Professor of Medicine, Oxford University

sally-davies

Dame Sally Davies

Chief Medical Officer, Department of Health, UK Government

BLA00002-Elizabeth-Blackburn

Elizabeth Blackburn

Nobel Laureate, President, Salk Institute for Biological Studies

George-Sledge

George Sledge

Professor, Division Chief, Stanford University Medical Center

Jeffrey Bluestone

Jeffrey Bluestone

CEO and President, Parker Institute for Cancer Immunotherapy

Christopher Ianelli

Christopher Ianelli

Founder and Chief Executive Officer,  iSpecimen

Kenneth J. Pienta

Kenneth J. Pienta

Director, Brady Urological Institute, Johns Hopkins Medicine

Roy Beveridge

Roy Beveridge

Senior Vice President & Chief Medical Officer, Humana

Kimberly Blackwell

Kimberly Blackwell

Professor of Medicine, Assistant Prof. of Radiation Oncology, Duke Cancer Institute

Joshua Denny

Joshua Denny

Professor of Biomedical Informatics & Medicine, Vanderbilt University Medical Center

Edward S. Kim

Edward S. Kim

Chair, Solid Tumor and Investigational Therapeutics, Levine Cancer Institute

Howard L. McLeod

Howard L. McLeod

Medical Director, Personalized Medicine Institute, Moffitt Cancer Center

Lee Newcomer

Lee Newcomer

SVP, UnitedHealthcare Oncology and Genetics

Vinod Khosla

Vinod Khosla

Partner and Founder of Khosla Ventures

Troy Brennan

Troy Brennan

Executive VP & CMO, CVS Health

Ira Mellman

Ira Mellman

VP, Cancer Immunology, Genentech

Event Highlights

When
January 22, 2018 8:00am to January 24, 2018 5:00pm
Where
Computer History Museum
1401 N Shoreline Blvd
Mountain View, CA 94043
Cost
$1850 by January 19th, 2018
Registration
3-Day Access to Talks, Exhibition & Reception:
See Registration Details

Registration: PMWC Conferences

Silicon Valley Jan 22-24, 2018

65+ Sessions 4 Tracks
350+ Speaker lineup
Access to the exhibition
Breakfast & lunch refreshments
Networking App
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help.